nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—BMP2K—synovial membrane of synovial joint—psoriatic arthritis	0.0308	0.141	CbGeAlD
Ruxolitinib—Tuberculosis—Dexamethasone—psoriatic arthritis	0.014	0.0726	CcSEcCtD
Ruxolitinib—Tuberculosis—Betamethasone—psoriatic arthritis	0.014	0.0726	CcSEcCtD
Ruxolitinib—PLK1—skin of body—psoriatic arthritis	0.0128	0.0584	CbGeAlD
Ruxolitinib—Tuberculosis—Prednisone—psoriatic arthritis	0.0122	0.0632	CcSEcCtD
Ruxolitinib—PRKCE—tendon—psoriatic arthritis	0.0101	0.0463	CbGeAlD
Ruxolitinib—RPS6KA6—tendon—psoriatic arthritis	0.00971	0.0444	CbGeAlD
Ruxolitinib—JAK1—skin of body—psoriatic arthritis	0.00817	0.0374	CbGeAlD
Ruxolitinib—CAMK1—tendon—psoriatic arthritis	0.00758	0.0347	CbGeAlD
Ruxolitinib—MARK2—tendon—psoriatic arthritis	0.00736	0.0337	CbGeAlD
Ruxolitinib—Gastrointestinal haemorrhage—Auranofin—psoriatic arthritis	0.00696	0.0362	CcSEcCtD
Ruxolitinib—BMPR2—skin of body—psoriatic arthritis	0.00683	0.0313	CbGeAlD
Ruxolitinib—TAOK2—tendon—psoriatic arthritis	0.00681	0.0312	CbGeAlD
Ruxolitinib—JAK1—tendon—psoriatic arthritis	0.00622	0.0285	CbGeAlD
Ruxolitinib—DCLK1—tendon—psoriatic arthritis	0.00622	0.0285	CbGeAlD
Ruxolitinib—CAMK1D—tendon—psoriatic arthritis	0.00607	0.0278	CbGeAlD
Ruxolitinib—PHKG2—tendon—psoriatic arthritis	0.00603	0.0276	CbGeAlD
Ruxolitinib—DAPK2—tendon—psoriatic arthritis	0.00593	0.0271	CbGeAlD
Ruxolitinib—STK16—tendon—psoriatic arthritis	0.00584	0.0267	CbGeAlD
Ruxolitinib—HIPK2—tendon—psoriatic arthritis	0.00581	0.0266	CbGeAlD
Ruxolitinib—Pancytopenia—Auranofin—psoriatic arthritis	0.00571	0.0297	CcSEcCtD
Ruxolitinib—Neutropenia—Auranofin—psoriatic arthritis	0.00562	0.0292	CcSEcCtD
Ruxolitinib—DAPK3—tendon—psoriatic arthritis	0.00558	0.0255	CbGeAlD
Ruxolitinib—CLK2—tendon—psoriatic arthritis	0.00552	0.0253	CbGeAlD
Ruxolitinib—Weight decreased—Auranofin—psoriatic arthritis	0.00544	0.0283	CcSEcCtD
Ruxolitinib—TYK2—skin of body—psoriatic arthritis	0.0054	0.0247	CbGeAlD
Ruxolitinib—BMPR2—tendon—psoriatic arthritis	0.0052	0.0238	CbGeAlD
Ruxolitinib—Haematuria—Auranofin—psoriatic arthritis	0.00511	0.0266	CcSEcCtD
Ruxolitinib—JAK2—skin of body—psoriatic arthritis	0.00491	0.0225	CbGeAlD
Ruxolitinib—MAP3K3—skin of body—psoriatic arthritis	0.00474	0.0217	CbGeAlD
Ruxolitinib—CAMK2G—tendon—psoriatic arthritis	0.00465	0.0213	CbGeAlD
Ruxolitinib—BMP2K—tendon—psoriatic arthritis	0.00465	0.0213	CbGeAlD
Ruxolitinib—LRRK2—tendon—psoriatic arthritis	0.00461	0.0211	CbGeAlD
Ruxolitinib—MAP3K7—tendon—psoriatic arthritis	0.00419	0.0192	CbGeAlD
Ruxolitinib—Flatulence—Auranofin—psoriatic arthritis	0.00413	0.0215	CcSEcCtD
Ruxolitinib—TYK2—tendon—psoriatic arthritis	0.00411	0.0188	CbGeAlD
Ruxolitinib—MKNK2—tendon—psoriatic arthritis	0.00406	0.0186	CbGeAlD
Ruxolitinib—IRAK1—tendon—psoriatic arthritis	0.00406	0.0186	CbGeAlD
Ruxolitinib—RET—tendon—psoriatic arthritis	0.00396	0.0181	CbGeAlD
Ruxolitinib—Anaemia—Auranofin—psoriatic arthritis	0.00387	0.0201	CcSEcCtD
Ruxolitinib—JAK2—tendon—psoriatic arthritis	0.00374	0.0171	CbGeAlD
Ruxolitinib—MAP3K3—tendon—psoriatic arthritis	0.00361	0.0165	CbGeAlD
Ruxolitinib—Thrombocytopenia—Auranofin—psoriatic arthritis	0.00335	0.0174	CcSEcCtD
Ruxolitinib—TAOK3—tendon—psoriatic arthritis	0.00329	0.015	CbGeAlD
Ruxolitinib—Contusion—Dexamethasone—psoriatic arthritis	0.00292	0.0152	CcSEcCtD
Ruxolitinib—Contusion—Betamethasone—psoriatic arthritis	0.00292	0.0152	CcSEcCtD
Ruxolitinib—Contusion—Prednisone—psoriatic arthritis	0.00255	0.0132	CcSEcCtD
Ruxolitinib—Herpes zoster—Methotrexate—psoriatic arthritis	0.00246	0.0128	CcSEcCtD
Ruxolitinib—Pruritus—Auranofin—psoriatic arthritis	0.00242	0.0126	CcSEcCtD
Ruxolitinib—Hypercholesterolaemia—Prednisone—psoriatic arthritis	0.00235	0.0122	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Methylprednisolone—psoriatic arthritis	0.0018	0.00933	CcSEcCtD
Ruxolitinib—Weight increased—Prednisolone—psoriatic arthritis	0.00174	0.00907	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Prednisone—psoriatic arthritis	0.00161	0.00838	CcSEcCtD
Ruxolitinib—Weight increased—Triamcinolone—psoriatic arthritis	0.0016	0.00834	CcSEcCtD
Ruxolitinib—Weight increased—Methylprednisolone—psoriatic arthritis	0.0016	0.00832	CcSEcCtD
Ruxolitinib—Infestation—Methylprednisolone—psoriatic arthritis	0.00157	0.00815	CcSEcCtD
Ruxolitinib—Infestation NOS—Methylprednisolone—psoriatic arthritis	0.00157	0.00815	CcSEcCtD
Ruxolitinib—Haemoglobin—Prednisolone—psoriatic arthritis	0.00154	0.00802	CcSEcCtD
Ruxolitinib—Haemorrhage—Prednisolone—psoriatic arthritis	0.00153	0.00798	CcSEcCtD
Ruxolitinib—Epistaxis—Triamcinolone—psoriatic arthritis	0.00148	0.00771	CcSEcCtD
Ruxolitinib—Weight increased—Dexamethasone—psoriatic arthritis	0.00146	0.00757	CcSEcCtD
Ruxolitinib—Weight increased—Betamethasone—psoriatic arthritis	0.00146	0.00757	CcSEcCtD
Ruxolitinib—Weight decreased—Betamethasone—psoriatic arthritis	0.00145	0.00752	CcSEcCtD
Ruxolitinib—Weight decreased—Dexamethasone—psoriatic arthritis	0.00145	0.00752	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Prednisone—psoriatic arthritis	0.00142	0.00739	CcSEcCtD
Ruxolitinib—Haemoglobin—Triamcinolone—psoriatic arthritis	0.00142	0.00737	CcSEcCtD
Ruxolitinib—Haemoglobin—Methylprednisolone—psoriatic arthritis	0.00142	0.00736	CcSEcCtD
Ruxolitinib—Haemorrhage—Triamcinolone—psoriatic arthritis	0.00141	0.00734	CcSEcCtD
Ruxolitinib—Haemorrhage—Methylprednisolone—psoriatic arthritis	0.00141	0.00732	CcSEcCtD
Ruxolitinib—TYK2—Interferon alpha/beta signaling—HLA-B—psoriatic arthritis	0.00136	0.00231	CbGpPWpGaD
Ruxolitinib—TYK2—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NOD2—psoriatic arthritis	0.00135	0.0023	CbGpPWpGaD
Ruxolitinib—TYK2—MyD88 dependent cascade initiated on endosome—NOD2—psoriatic arthritis	0.00133	0.00226	CbGpPWpGaD
Ruxolitinib—MAP3K7—MyD88 cascade initiated on plasma membrane—NOD2—psoriatic arthritis	0.00133	0.00225	CbGpPWpGaD
Ruxolitinib—MAP3K7—Toll-like Receptor Signaling Pathway—IL12B—psoriatic arthritis	0.00133	0.00225	CbGpPWpGaD
Ruxolitinib—IRAK1—Toll Like Receptor 9 (TLR9) Cascade—NOD2—psoriatic arthritis	0.00132	0.00224	CbGpPWpGaD
Ruxolitinib—MAP3K7—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NOD2—psoriatic arthritis	0.00131	0.00223	CbGpPWpGaD
Ruxolitinib—JAK2—Type II interferon signaling (IFNG)—NOS2—psoriatic arthritis	0.00131	0.00222	CbGpPWpGaD
Ruxolitinib—JAK2—IL23-mediated signaling events—NOS2—psoriatic arthritis	0.00131	0.00222	CbGpPWpGaD
Ruxolitinib—Neutropenia—Prednisone—psoriatic arthritis	0.0013	0.00677	CcSEcCtD
Ruxolitinib—IRAK1—MyD88:Mal cascade initiated on plasma membrane—NOD2—psoriatic arthritis	0.0013	0.00221	CbGpPWpGaD
Ruxolitinib—MAP3K7—MyD88 dependent cascade initiated on endosome—NOD2—psoriatic arthritis	0.00129	0.00219	CbGpPWpGaD
Ruxolitinib—IRAK1—EBV LMP1 signaling—TNF—psoriatic arthritis	0.00129	0.00219	CbGpPWpGaD
Ruxolitinib—Haemoglobin—Betamethasone—psoriatic arthritis	0.00129	0.00669	CcSEcCtD
Ruxolitinib—Haemoglobin—Dexamethasone—psoriatic arthritis	0.00129	0.00669	CcSEcCtD
Ruxolitinib—TYK2—Toll Like Receptor 9 (TLR9) Cascade—NOD2—psoriatic arthritis	0.00128	0.00218	CbGpPWpGaD
Ruxolitinib—Haemorrhage—Dexamethasone—psoriatic arthritis	0.00128	0.00666	CcSEcCtD
Ruxolitinib—Haemorrhage—Betamethasone—psoriatic arthritis	0.00128	0.00666	CcSEcCtD
Ruxolitinib—ROCK1—amb2 Integrin signaling—TNF—psoriatic arthritis	0.00128	0.00217	CbGpPWpGaD
Ruxolitinib—DYRK1A—Circadian rythm related genes—NOS2—psoriatic arthritis	0.00128	0.00217	CbGpPWpGaD
Ruxolitinib—JAK2—IL-6 signaling pathway—CRP—psoriatic arthritis	0.00127	0.00216	CbGpPWpGaD
Ruxolitinib—Weight increased—Prednisone—psoriatic arthritis	0.00127	0.00659	CcSEcCtD
Ruxolitinib—TYK2—MyD88:Mal cascade initiated on plasma membrane—NOD2—psoriatic arthritis	0.00126	0.00214	CbGpPWpGaD
Ruxolitinib—Weight decreased—Prednisone—psoriatic arthritis	0.00126	0.00655	CcSEcCtD
Ruxolitinib—IRAK1—MyD88-independent cascade—NOD2—psoriatic arthritis	0.00125	0.00212	CbGpPWpGaD
Ruxolitinib—MAP3K7—Toll Like Receptor 9 (TLR9) Cascade—NOD2—psoriatic arthritis	0.00124	0.00211	CbGpPWpGaD
Ruxolitinib—JAK1—Toll-Like Receptors Cascades—NOD2—psoriatic arthritis	0.00124	0.0021	CbGpPWpGaD
Ruxolitinib—TYK2—IL12-mediated signaling events—HLA-DRB1—psoriatic arthritis	0.00123	0.00209	CbGpPWpGaD
Ruxolitinib—Malnutrition—Methylprednisolone—psoriatic arthritis	0.00123	0.00637	CcSEcCtD
Ruxolitinib—CAMK2G—Cytokine Signaling in Immune system—HLA-C—psoriatic arthritis	0.00122	0.00208	CbGpPWpGaD
Ruxolitinib—MAP3K7—MyD88:Mal cascade initiated on plasma membrane—NOD2—psoriatic arthritis	0.00122	0.00208	CbGpPWpGaD
Ruxolitinib—MAP3K7—EBV LMP1 signaling—TNF—psoriatic arthritis	0.00121	0.00206	CbGpPWpGaD
Ruxolitinib—TYK2—MyD88-independent cascade—NOD2—psoriatic arthritis	0.00121	0.00205	CbGpPWpGaD
Ruxolitinib—MAP3K7—TCR signaling—HLA-DRB1—psoriatic arthritis	0.00121	0.00205	CbGpPWpGaD
Ruxolitinib—MAP3K3—TNF receptor signaling pathway —TNF—psoriatic arthritis	0.0012	0.00204	CbGpPWpGaD
Ruxolitinib—MAP3K3—Cytokine Signaling in Immune system—HLA-C—psoriatic arthritis	0.0012	0.00203	CbGpPWpGaD
Ruxolitinib—JAK2—IL6-mediated signaling events—CRP—psoriatic arthritis	0.00118	0.00201	CbGpPWpGaD
Ruxolitinib—MAP3K7—MyD88-independent cascade—NOD2—psoriatic arthritis	0.00117	0.00199	CbGpPWpGaD
Ruxolitinib—TYK2—IL12-mediated signaling events—NOS2—psoriatic arthritis	0.00117	0.00199	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling by Interleukins—NOD2—psoriatic arthritis	0.00116	0.00197	CbGpPWpGaD
Ruxolitinib—JAK2—TRAF6 Mediated Induction of proinflammatory cytokines—NOD2—psoriatic arthritis	0.00115	0.00194	CbGpPWpGaD
Ruxolitinib—MAP3K7—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.00114	0.00194	CbGpPWpGaD
Ruxolitinib—PRKCE—DAP12 interactions—HLA-B—psoriatic arthritis	0.00114	0.00194	CbGpPWpGaD
Ruxolitinib—TAOK2—MAPK Signaling Pathway—TNF—psoriatic arthritis	0.00114	0.00193	CbGpPWpGaD
Ruxolitinib—TYK2—IL27-mediated signaling events—TNF—psoriatic arthritis	0.00113	0.00193	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by Interleukins—NOD2—psoriatic arthritis	0.00113	0.00192	CbGpPWpGaD
Ruxolitinib—JAK3—Cytokine Signaling in Immune system—HLA-C—psoriatic arthritis	0.00113	0.00191	CbGpPWpGaD
Ruxolitinib—IRAK1—Activated TLR4 signalling—NOD2—psoriatic arthritis	0.00112	0.0019	CbGpPWpGaD
Ruxolitinib—Haemoglobin—Prednisone—psoriatic arthritis	0.00112	0.00583	CcSEcCtD
Ruxolitinib—Haemorrhage—Prednisone—psoriatic arthritis	0.00112	0.0058	CcSEcCtD
Ruxolitinib—Pancytopenia—Methotrexate—psoriatic arthritis	0.00111	0.00575	CcSEcCtD
Ruxolitinib—IRAK1—Regulation of toll-like receptor signaling pathway—IL12B—psoriatic arthritis	0.0011	0.00186	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling by Interleukins—NOD2—psoriatic arthritis	0.00109	0.00186	CbGpPWpGaD
Ruxolitinib—Neutropenia—Methotrexate—psoriatic arthritis	0.00109	0.00566	CcSEcCtD
Ruxolitinib—TYK2—Activated TLR4 signalling—NOD2—psoriatic arthritis	0.00109	0.00185	CbGpPWpGaD
Ruxolitinib—CAMK2G—Interferon Signaling—HLA-B—psoriatic arthritis	0.00108	0.00184	CbGpPWpGaD
Ruxolitinib—DAPK2—Apoptosis—TNF—psoriatic arthritis	0.00108	0.00184	CbGpPWpGaD
Ruxolitinib—DAPK3—Apoptosis—TNF—psoriatic arthritis	0.00108	0.00184	CbGpPWpGaD
Ruxolitinib—TYK2—Interferon Signaling—HLA-C—psoriatic arthritis	0.00107	0.00182	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—MEFV—psoriatic arthritis	0.00106	0.0018	CbGpPWpGaD
Ruxolitinib—MAP3K7—Activated TLR4 signalling—NOD2—psoriatic arthritis	0.00106	0.00179	CbGpPWpGaD
Ruxolitinib—IRAK1—Toll Like Receptor 4 (TLR4) Cascade—NOD2—psoriatic arthritis	0.00105	0.00179	CbGpPWpGaD
Ruxolitinib—Infestation—Methotrexate—psoriatic arthritis	0.00104	0.0054	CcSEcCtD
Ruxolitinib—Infestation NOS—Methotrexate—psoriatic arthritis	0.00104	0.0054	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—psoriatic arthritis	0.00104	0.00539	CcSEcCtD
Ruxolitinib—JAK2—MyD88 cascade initiated on plasma membrane—NOD2—psoriatic arthritis	0.00104	0.00176	CbGpPWpGaD
Ruxolitinib—MAP3K7—Regulation of toll-like receptor signaling pathway—IL12B—psoriatic arthritis	0.00103	0.00176	CbGpPWpGaD
Ruxolitinib—TYK2—DAP12 interactions—HLA-C—psoriatic arthritis	0.00103	0.00175	CbGpPWpGaD
Ruxolitinib—JAK2—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NOD2—psoriatic arthritis	0.00103	0.00174	CbGpPWpGaD
Ruxolitinib—TYK2—Toll Like Receptor 4 (TLR4) Cascade—NOD2—psoriatic arthritis	0.00102	0.00174	CbGpPWpGaD
Ruxolitinib—MAP3K7—B Cell Activation—REL—psoriatic arthritis	0.00101	0.00171	CbGpPWpGaD
Ruxolitinib—JAK2—MyD88 dependent cascade initiated on endosome—NOD2—psoriatic arthritis	0.00101	0.00171	CbGpPWpGaD
Ruxolitinib—PRKCE—Downstream signaling in naïve CD8+ T cells—TNF—psoriatic arthritis	0.001	0.00171	CbGpPWpGaD
Ruxolitinib—Infection—Triamcinolone—psoriatic arthritis	0.000996	0.00518	CcSEcCtD
Ruxolitinib—Infection—Methylprednisolone—psoriatic arthritis	0.000994	0.00517	CcSEcCtD
Ruxolitinib—MAP3K7—Toll Like Receptor 4 (TLR4) Cascade—NOD2—psoriatic arthritis	0.000993	0.00169	CbGpPWpGaD
Ruxolitinib—Haematuria—Methotrexate—psoriatic arthritis	0.00099	0.00515	CcSEcCtD
Ruxolitinib—JAK2—Interferon gamma signaling—HLA-B—psoriatic arthritis	0.000984	0.00167	CbGpPWpGaD
Ruxolitinib—Hepatobiliary disease—Methotrexate—psoriatic arthritis	0.000982	0.0051	CcSEcCtD
Ruxolitinib—Nervous system disorder—Methylprednisolone—psoriatic arthritis	0.000981	0.0051	CcSEcCtD
Ruxolitinib—Epistaxis—Methotrexate—psoriatic arthritis	0.000979	0.00509	CcSEcCtD
Ruxolitinib—JAK2—Toll Like Receptor 9 (TLR9) Cascade—NOD2—psoriatic arthritis	0.000972	0.00165	CbGpPWpGaD
Ruxolitinib—Skin disorder—Methylprednisolone—psoriatic arthritis	0.000972	0.00505	CcSEcCtD
Ruxolitinib—Malnutrition—Prednisone—psoriatic arthritis	0.000971	0.00505	CcSEcCtD
Ruxolitinib—JAK1—Cytokine Signaling in Immune system—HLA-C—psoriatic arthritis	0.00097	0.00165	CbGpPWpGaD
Ruxolitinib—JAK2—MyD88:Mal cascade initiated on plasma membrane—NOD2—psoriatic arthritis	0.000956	0.00162	CbGpPWpGaD
Ruxolitinib—IRAK1—Toll-Like Receptors Cascades—NOD2—psoriatic arthritis	0.000939	0.00159	CbGpPWpGaD
Ruxolitinib—Haemoglobin—Methotrexate—psoriatic arthritis	0.000937	0.00487	CcSEcCtD
Ruxolitinib—Haemorrhage—Methotrexate—psoriatic arthritis	0.000932	0.00484	CcSEcCtD
Ruxolitinib—JAK2—IL12-mediated signaling events—HLA-DRB1—psoriatic arthritis	0.000932	0.00158	CbGpPWpGaD
Ruxolitinib—CAMK2G—Interferon Signaling—HLA-DRB1—psoriatic arthritis	0.000918	0.00156	CbGpPWpGaD
Ruxolitinib—JAK2—MyD88-independent cascade—NOD2—psoriatic arthritis	0.000917	0.00156	CbGpPWpGaD
Ruxolitinib—TYK2—Toll-Like Receptors Cascades—NOD2—psoriatic arthritis	0.000912	0.00155	CbGpPWpGaD
Ruxolitinib—Infection—Betamethasone—psoriatic arthritis	0.000904	0.0047	CcSEcCtD
Ruxolitinib—Infection—Dexamethasone—psoriatic arthritis	0.000904	0.0047	CcSEcCtD
Ruxolitinib—CAMK2G—Cytokine Signaling in Immune system—NOD2—psoriatic arthritis	0.0009	0.00153	CbGpPWpGaD
Ruxolitinib—Anaemia—Prednisone—psoriatic arthritis	0.000897	0.00466	CcSEcCtD
Ruxolitinib—Nervous system disorder—Betamethasone—psoriatic arthritis	0.000892	0.00464	CcSEcCtD
Ruxolitinib—Nervous system disorder—Dexamethasone—psoriatic arthritis	0.000892	0.00464	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Dexamethasone—psoriatic arthritis	0.000891	0.00463	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Betamethasone—psoriatic arthritis	0.000891	0.00463	CcSEcCtD
Ruxolitinib—JAK2—IL12-mediated signaling events—NOS2—psoriatic arthritis	0.000887	0.00151	CbGpPWpGaD
Ruxolitinib—MAP3K7—Toll-Like Receptors Cascades—NOD2—psoriatic arthritis	0.000884	0.0015	CbGpPWpGaD
Ruxolitinib—MAP3K3—Cytokine Signaling in Immune system—NOD2—psoriatic arthritis	0.000879	0.00149	CbGpPWpGaD
Ruxolitinib—Fatigue—Triamcinolone—psoriatic arthritis	0.000864	0.00449	CcSEcCtD
Ruxolitinib—Fatigue—Methylprednisolone—psoriatic arthritis	0.000863	0.00448	CcSEcCtD
Ruxolitinib—LRRK2—MAPK Signaling Pathway—TNF—psoriatic arthritis	0.000862	0.00146	CbGpPWpGaD
Ruxolitinib—JAK2—IL27-mediated signaling events—TNF—psoriatic arthritis	0.00086	0.00146	CbGpPWpGaD
Ruxolitinib—JAK1—Interferon Signaling—HLA-B—psoriatic arthritis	0.000859	0.00146	CbGpPWpGaD
Ruxolitinib—JAK1—TGF-beta Receptor Signaling—TNF—psoriatic arthritis	0.000857	0.00145	CbGpPWpGaD
Ruxolitinib—TYK2—IL23-mediated signaling events—TNF—psoriatic arthritis	0.000856	0.00145	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by Interleukins—NOD2—psoriatic arthritis	0.000855	0.00145	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—MEFV—psoriatic arthritis	0.000853	0.00145	CbGpPWpGaD
Ruxolitinib—PLK1—TNF alpha Signaling Pathway—TNF—psoriatic arthritis	0.000845	0.00144	CbGpPWpGaD
Ruxolitinib—JAK2—Interferon gamma signaling—HLA-DRB1—psoriatic arthritis	0.000833	0.00141	CbGpPWpGaD
Ruxolitinib—JAK3—Cytokine Signaling in Immune system—NOD2—psoriatic arthritis	0.000829	0.00141	CbGpPWpGaD
Ruxolitinib—JAK1—DAP12 interactions—HLA-B—psoriatic arthritis	0.000828	0.00141	CbGpPWpGaD
Ruxolitinib—JAK2—Activated TLR4 signalling—NOD2—psoriatic arthritis	0.000825	0.0014	CbGpPWpGaD
Ruxolitinib—JAK2—AGE/RAGE pathway—NOS2—psoriatic arthritis	0.000822	0.0014	CbGpPWpGaD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriatic arthritis	0.000821	0.00427	CcSEcCtD
Ruxolitinib—JAK2—Interferon Signaling—HLA-C—psoriatic arthritis	0.000813	0.00138	CbGpPWpGaD
Ruxolitinib—Malnutrition—Methotrexate—psoriatic arthritis	0.000811	0.00422	CcSEcCtD
Ruxolitinib—IRAK1—Innate Immune System—MEFV—psoriatic arthritis	0.000808	0.00137	CbGpPWpGaD
Ruxolitinib—Body temperature increased—Triamcinolone—psoriatic arthritis	0.000793	0.00412	CcSEcCtD
Ruxolitinib—Infection—Prednisone—psoriatic arthritis	0.000787	0.00409	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	0.000785	0.00408	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	0.000785	0.00408	CcSEcCtD
Ruxolitinib—TYK2—Innate Immune System—MEFV—psoriatic arthritis	0.000785	0.00133	CbGpPWpGaD
Ruxolitinib—Fatigue—Betamethasone—psoriatic arthritis	0.000784	0.00408	CcSEcCtD
Ruxolitinib—Fatigue—Dexamethasone—psoriatic arthritis	0.000784	0.00408	CcSEcCtD
Ruxolitinib—JAK2—DAP12 interactions—HLA-C—psoriatic arthritis	0.000783	0.00133	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—MEFV—psoriatic arthritis	0.000781	0.00133	CbGpPWpGaD
Ruxolitinib—Nervous system disorder—Prednisone—psoriatic arthritis	0.000777	0.00404	CcSEcCtD
Ruxolitinib—JAK2—Toll Like Receptor 4 (TLR4) Cascade—NOD2—psoriatic arthritis	0.000776	0.00132	CbGpPWpGaD
Ruxolitinib—Skin disorder—Prednisone—psoriatic arthritis	0.00077	0.004	CcSEcCtD
Ruxolitinib—MAP3K3—Immune System—MEFV—psoriatic arthritis	0.000763	0.00129	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—MEFV—psoriatic arthritis	0.000761	0.00129	CbGpPWpGaD
Ruxolitinib—Anaemia—Methotrexate—psoriatic arthritis	0.00075	0.0039	CcSEcCtD
Ruxolitinib—MAP3K7—TWEAK Signaling Pathway—TNF—psoriatic arthritis	0.00075	0.00127	CbGpPWpGaD
Ruxolitinib—MAP3K7—FAS pathway and Stress induction of HSP regulation—TNF—psoriatic arthritis	0.00075	0.00127	CbGpPWpGaD
Ruxolitinib—PRKCE—Innate Immune System—HLA-C—psoriatic arthritis	0.000749	0.00127	CbGpPWpGaD
Ruxolitinib—IRAK1—Cytokine Signaling in Immune system—HLA-C—psoriatic arthritis	0.000738	0.00125	CbGpPWpGaD
Ruxolitinib—JAK1—Interferon Signaling—HLA-DRB1—psoriatic arthritis	0.000727	0.00123	CbGpPWpGaD
Ruxolitinib—CAMK2G—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	0.000724	0.00123	CbGpPWpGaD
Ruxolitinib—Dizziness—Prednisolone—psoriatic arthritis	0.000721	0.00375	CcSEcCtD
Ruxolitinib—JAK3—Immune System—MEFV—psoriatic arthritis	0.00072	0.00122	CbGpPWpGaD
Ruxolitinib—Asthenia—Triamcinolone—psoriatic arthritis	0.000719	0.00374	CcSEcCtD
Ruxolitinib—Body temperature increased—Betamethasone—psoriatic arthritis	0.000719	0.00374	CcSEcCtD
Ruxolitinib—Body temperature increased—Dexamethasone—psoriatic arthritis	0.000719	0.00374	CcSEcCtD
Ruxolitinib—PRKG2—Hemostasis—NOS2—psoriatic arthritis	0.000719	0.00122	CbGpPWpGaD
Ruxolitinib—Asthenia—Methylprednisolone—psoriatic arthritis	0.000718	0.00373	CcSEcCtD
Ruxolitinib—TYK2—Cytokine Signaling in Immune system—HLA-C—psoriatic arthritis	0.000716	0.00122	CbGpPWpGaD
Ruxolitinib—JAK1—Cytokine Signaling in Immune system—NOD2—psoriatic arthritis	0.000714	0.00121	CbGpPWpGaD
Ruxolitinib—JAK2—CXCR4-mediated signaling events—HLA-DRB1—psoriatic arthritis	0.000712	0.00121	CbGpPWpGaD
Ruxolitinib—Pruritus—Triamcinolone—psoriatic arthritis	0.000709	0.00369	CcSEcCtD
Ruxolitinib—Pruritus—Methylprednisolone—psoriatic arthritis	0.000708	0.00368	CcSEcCtD
Ruxolitinib—MAP3K3—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	0.000707	0.0012	CbGpPWpGaD
Ruxolitinib—MAP3K7—TNF receptor signaling pathway —TNF—psoriatic arthritis	0.000697	0.00118	CbGpPWpGaD
Ruxolitinib—MAP3K7—Cytokine Signaling in Immune system—HLA-C—psoriatic arthritis	0.000695	0.00118	CbGpPWpGaD
Ruxolitinib—JAK2—Toll-Like Receptors Cascades—NOD2—psoriatic arthritis	0.000691	0.00117	CbGpPWpGaD
Ruxolitinib—MAP3K3—TNF alpha Signaling Pathway—TNF—psoriatic arthritis	0.000689	0.00117	CbGpPWpGaD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriatic arthritis	0.000686	0.00357	CcSEcCtD
Ruxolitinib—Fatigue—Prednisone—psoriatic arthritis	0.000683	0.00355	CcSEcCtD
Ruxolitinib—Headache—Prednisolone—psoriatic arthritis	0.000683	0.00355	CcSEcCtD
Ruxolitinib—JAK3—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	0.000667	0.00113	CbGpPWpGaD
Ruxolitinib—Dizziness—Triamcinolone—psoriatic arthritis	0.000663	0.00345	CcSEcCtD
Ruxolitinib—Dizziness—Methylprednisolone—psoriatic arthritis	0.000662	0.00344	CcSEcCtD
Ruxolitinib—Infection—Methotrexate—psoriatic arthritis	0.000658	0.00342	CcSEcCtD
Ruxolitinib—Asthenia—Betamethasone—psoriatic arthritis	0.000653	0.00339	CcSEcCtD
Ruxolitinib—Asthenia—Dexamethasone—psoriatic arthritis	0.000653	0.00339	CcSEcCtD
Ruxolitinib—Nervous system disorder—Methotrexate—psoriatic arthritis	0.000649	0.00338	CcSEcCtD
Ruxolitinib—JAK2—IL23-mediated signaling events—TNF—psoriatic arthritis	0.000648	0.0011	CbGpPWpGaD
Ruxolitinib—Thrombocytopenia—Methotrexate—psoriatic arthritis	0.000648	0.00337	CcSEcCtD
Ruxolitinib—Pruritus—Betamethasone—psoriatic arthritis	0.000644	0.00335	CcSEcCtD
Ruxolitinib—Pruritus—Dexamethasone—psoriatic arthritis	0.000644	0.00335	CcSEcCtD
Ruxolitinib—Skin disorder—Methotrexate—psoriatic arthritis	0.000643	0.00334	CcSEcCtD
Ruxolitinib—TYK2—Interferon Signaling—HLA-B—psoriatic arthritis	0.000634	0.00108	CbGpPWpGaD
Ruxolitinib—RET—SIDS Susceptibility Pathways—TNF—psoriatic arthritis	0.000634	0.00108	CbGpPWpGaD
Ruxolitinib—Headache—Triamcinolone—psoriatic arthritis	0.000628	0.00327	CcSEcCtD
Ruxolitinib—Headache—Methylprednisolone—psoriatic arthritis	0.000627	0.00326	CcSEcCtD
Ruxolitinib—Body temperature increased—Prednisone—psoriatic arthritis	0.000626	0.00326	CcSEcCtD
Ruxolitinib—JAK1—Immune System—MEFV—psoriatic arthritis	0.000619	0.00105	CbGpPWpGaD
Ruxolitinib—CAMK2G—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	0.000613	0.00104	CbGpPWpGaD
Ruxolitinib—TYK2—DAP12 interactions—HLA-B—psoriatic arthritis	0.000611	0.00104	CbGpPWpGaD
Ruxolitinib—PLK1—Regulation of toll-like receptor signaling pathway—TNF—psoriatic arthritis	0.000608	0.00103	CbGpPWpGaD
Ruxolitinib—MAP3K7—Cardiac Hypertrophic Response—TNF—psoriatic arthritis	0.000604	0.00103	CbGpPWpGaD
Ruxolitinib—Dizziness—Betamethasone—psoriatic arthritis	0.000602	0.00313	CcSEcCtD
Ruxolitinib—Dizziness—Dexamethasone—psoriatic arthritis	0.000602	0.00313	CcSEcCtD
Ruxolitinib—MAP3K3—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	0.000599	0.00102	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—MEFV—psoriatic arthritis	0.000595	0.00101	CbGpPWpGaD
Ruxolitinib—ROCK1—MicroRNAs in cardiomyocyte hypertrophy—TNF—psoriatic arthritis	0.000592	0.001	CbGpPWpGaD
Ruxolitinib—JAK1—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	0.000574	0.000974	CbGpPWpGaD
Ruxolitinib—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	0.000572	0.00297	CcSEcCtD
Ruxolitinib—Fatigue—Methotrexate—psoriatic arthritis	0.000571	0.00297	CcSEcCtD
Ruxolitinib—Headache—Betamethasone—psoriatic arthritis	0.00057	0.00296	CcSEcCtD
Ruxolitinib—Headache—Dexamethasone—psoriatic arthritis	0.00057	0.00296	CcSEcCtD
Ruxolitinib—Asthenia—Prednisone—psoriatic arthritis	0.000568	0.00295	CcSEcCtD
Ruxolitinib—JAK3—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	0.000565	0.000958	CbGpPWpGaD
Ruxolitinib—Pruritus—Prednisone—psoriatic arthritis	0.000561	0.00291	CcSEcCtD
Ruxolitinib—PRKCE—Innate Immune System—NOD2—psoriatic arthritis	0.000551	0.000935	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—HLA-C—psoriatic arthritis	0.000544	0.000924	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—HLA-C—psoriatic arthritis	0.000543	0.000921	CbGpPWpGaD
Ruxolitinib—IRAK1—Cytokine Signaling in Immune system—NOD2—psoriatic arthritis	0.000543	0.000921	CbGpPWpGaD
Ruxolitinib—TYK2—Interferon Signaling—HLA-DRB1—psoriatic arthritis	0.000537	0.000911	CbGpPWpGaD
Ruxolitinib—TYK2—Cytokine Signaling in Immune system—NOD2—psoriatic arthritis	0.000527	0.000894	CbGpPWpGaD
Ruxolitinib—Dizziness—Prednisone—psoriatic arthritis	0.000524	0.00272	CcSEcCtD
Ruxolitinib—Body temperature increased—Methotrexate—psoriatic arthritis	0.000523	0.00272	CcSEcCtD
Ruxolitinib—MAP3K7—Cytokine Signaling in Immune system—NOD2—psoriatic arthritis	0.000511	0.000867	CbGpPWpGaD
Ruxolitinib—Headache—Prednisone—psoriatic arthritis	0.000496	0.00258	CcSEcCtD
Ruxolitinib—MAP3K2—MAPK Signaling Pathway—TNF—psoriatic arthritis	0.000495	0.00084	CbGpPWpGaD
Ruxolitinib—JAK1—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	0.000486	0.000824	CbGpPWpGaD
Ruxolitinib—JAK2—Interferon Signaling—HLA-B—psoriatic arthritis	0.000481	0.000816	CbGpPWpGaD
Ruxolitinib—Asthenia—Methotrexate—psoriatic arthritis	0.000475	0.00247	CcSEcCtD
Ruxolitinib—PRKCE—Immune System—REL—psoriatic arthritis	0.000474	0.000805	CbGpPWpGaD
Ruxolitinib—PLK1—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	0.000471	0.0008	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—MEFV—psoriatic arthritis	0.000471	0.000799	CbGpPWpGaD
Ruxolitinib—Pruritus—Methotrexate—psoriatic arthritis	0.000468	0.00244	CcSEcCtD
Ruxolitinib—JAK2—DAP12 interactions—HLA-B—psoriatic arthritis	0.000463	0.000786	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—MEFV—psoriatic arthritis	0.000457	0.000776	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—MEFV—psoriatic arthritis	0.000443	0.000752	CbGpPWpGaD
Ruxolitinib—PRKCE—Innate Immune System—HLA-B—psoriatic arthritis	0.000443	0.000752	CbGpPWpGaD
Ruxolitinib—Dizziness—Methotrexate—psoriatic arthritis	0.000438	0.00228	CcSEcCtD
Ruxolitinib—PRKCE—Immune System—HLA-C—psoriatic arthritis	0.000436	0.000741	CbGpPWpGaD
Ruxolitinib—IRAK1—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	0.000436	0.000741	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—REL—psoriatic arthritis	0.000434	0.000737	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—REL—psoriatic arthritis	0.000424	0.00072	CbGpPWpGaD
Ruxolitinib—TYK2—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	0.000424	0.000719	CbGpPWpGaD
Ruxolitinib—Headache—Methotrexate—psoriatic arthritis	0.000415	0.00216	CcSEcCtD
Ruxolitinib—IRAK1—Innate Immune System—HLA-C—psoriatic arthritis	0.000414	0.000702	CbGpPWpGaD
Ruxolitinib—MAP3K7—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	0.000411	0.000697	CbGpPWpGaD
Ruxolitinib—JAK2—Interferon Signaling—HLA-DRB1—psoriatic arthritis	0.000407	0.000691	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—REL—psoriatic arthritis	0.000406	0.00069	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—HLA-C—psoriatic arthritis	0.000402	0.000682	CbGpPWpGaD
Ruxolitinib—MAP3K7—TNF alpha Signaling Pathway—TNF—psoriatic arthritis	0.0004	0.00068	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—REL—psoriatic arthritis	0.0004	0.000679	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—NOD2—psoriatic arthritis	0.0004	0.000679	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—HLA-C—psoriatic arthritis	0.0004	0.000679	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—NOD2—psoriatic arthritis	0.000399	0.000678	CbGpPWpGaD
Ruxolitinib—PRKCE—Hemostasis—NOS2—psoriatic arthritis	0.000397	0.000673	CbGpPWpGaD
Ruxolitinib—PRKCE—Innate Immune System—CRP—psoriatic arthritis	0.000392	0.000665	CbGpPWpGaD
Ruxolitinib—IRAK1—Toll-like Receptor Signaling Pathway—TNF—psoriatic arthritis	0.000392	0.000665	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—HLA-C—psoriatic arthritis	0.000391	0.000663	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—HLA-C—psoriatic arthritis	0.00039	0.000661	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000374	0.000635	CbGpPWpGaD
Ruxolitinib—IRAK1—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	0.000369	0.000627	CbGpPWpGaD
Ruxolitinib—MAP3K7—Toll-like Receptor Signaling Pathway—TNF—psoriatic arthritis	0.000369	0.000626	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—HLA-C—psoriatic arthritis	0.000368	0.000625	CbGpPWpGaD
Ruxolitinib—ROCK1—Apoptosis—TNF—psoriatic arthritis	0.000362	0.000615	CbGpPWpGaD
Ruxolitinib—TYK2—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	0.000359	0.000609	CbGpPWpGaD
Ruxolitinib—RPS6KA6—Developmental Biology—TNF—psoriatic arthritis	0.000352	0.000598	CbGpPWpGaD
Ruxolitinib—MAP3K7—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	0.000348	0.00059	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—MEFV—psoriatic arthritis	0.000346	0.000588	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—REL—psoriatic arthritis	0.000344	0.000584	CbGpPWpGaD
Ruxolitinib—JAK3—Hemostasis—NOS2—psoriatic arthritis	0.000335	0.000568	CbGpPWpGaD
Ruxolitinib—GRK1—Disease—NOS2—psoriatic arthritis	0.000327	0.000555	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—HLA-B—psoriatic arthritis	0.000322	0.000546	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	0.000321	0.000545	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—NOD2—psoriatic arthritis	0.000321	0.000545	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—HLA-C—psoriatic arthritis	0.000317	0.000538	CbGpPWpGaD
Ruxolitinib—IRAK1—Regulation of toll-like receptor signaling pathway—TNF—psoriatic arthritis	0.000306	0.000519	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—HLA-C—psoriatic arthritis	0.000304	0.000517	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—NOD2—psoriatic arthritis	0.000304	0.000516	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—NOS2—psoriatic arthritis	0.000296	0.000502	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—NOD2—psoriatic arthritis	0.000295	0.000501	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—NOD2—psoriatic arthritis	0.000294	0.000499	CbGpPWpGaD
Ruxolitinib—JAK1—Hemostasis—NOS2—psoriatic arthritis	0.000288	0.000489	CbGpPWpGaD
Ruxolitinib—MAP3K7—Regulation of toll-like receptor signaling pathway—TNF—psoriatic arthritis	0.000288	0.000489	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—NOD2—psoriatic arthritis	0.000287	0.000487	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—NOD2—psoriatic arthritis	0.000286	0.000486	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—CRP—psoriatic arthritis	0.000284	0.000483	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	0.000272	0.000461	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—NOD2—psoriatic arthritis	0.000271	0.00046	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—REL—psoriatic arthritis	0.000262	0.000444	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—HLA-B—psoriatic arthritis	0.000258	0.000438	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—REL—psoriatic arthritis	0.000254	0.000431	CbGpPWpGaD
Ruxolitinib—MAP3K7—MAPK Signaling Pathway—TNF—psoriatic arthritis	0.000247	0.00042	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—REL—psoriatic arthritis	0.000247	0.000419	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—HLA-B—psoriatic arthritis	0.000245	0.000415	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—HLA-C—psoriatic arthritis	0.000241	0.000409	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—HLA-B—psoriatic arthritis	0.000238	0.000403	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—HLA-B—psoriatic arthritis	0.000236	0.000401	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—HLA-C—psoriatic arthritis	0.000234	0.000397	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—NOD2—psoriatic arthritis	0.000233	0.000396	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—HLA-B—psoriatic arthritis	0.000231	0.000392	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—HLA-B—psoriatic arthritis	0.00023	0.000391	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—CRP—psoriatic arthritis	0.000228	0.000387	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—HLA-C—psoriatic arthritis	0.000227	0.000385	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—NOD2—psoriatic arthritis	0.000224	0.00038	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000221	0.000376	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—HLA-DRB1—psoriatic arthritis	0.000218	0.000371	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—HLA-B—psoriatic arthritis	0.000218	0.00037	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—CRP—psoriatic arthritis	0.000216	0.000367	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—CRP—psoriatic arthritis	0.00021	0.000356	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—CRP—psoriatic arthritis	0.000209	0.000355	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—CRP—psoriatic arthritis	0.000204	0.000346	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—CRP—psoriatic arthritis	0.000204	0.000346	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—HLA-DRB1—psoriatic arthritis	0.0002	0.00034	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—HLA-DRB1—psoriatic arthritis	0.000195	0.000332	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—REL—psoriatic arthritis	0.000193	0.000327	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—CRP—psoriatic arthritis	0.000193	0.000327	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—NOS2—psoriatic arthritis	0.000192	0.000326	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—HLA-B—psoriatic arthritis	0.000187	0.000318	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	0.000187	0.000318	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—HLA-DRB1—psoriatic arthritis	0.000184	0.000313	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—HLA-B—psoriatic arthritis	0.00018	0.000306	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HLA-C—psoriatic arthritis	0.000177	0.000301	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—NOD2—psoriatic arthritis	0.000177	0.000301	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—NOD2—psoriatic arthritis	0.000172	0.000292	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—NOD2—psoriatic arthritis	0.000167	0.000283	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—CRP—psoriatic arthritis	0.000166	0.000281	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—NOS2—psoriatic arthritis	0.000161	0.000274	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—CRP—psoriatic arthritis	0.000159	0.00027	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—HLA-DRB1—psoriatic arthritis	0.000159	0.000269	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—TNF—psoriatic arthritis	0.000146	0.000247	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—TNF—psoriatic arthritis	0.000143	0.000243	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—HLA-B—psoriatic arthritis	0.000143	0.000242	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—NOS2—psoriatic arthritis	0.000139	0.000237	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—HLA-B—psoriatic arthritis	0.000138	0.000235	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—HLA-B—psoriatic arthritis	0.000134	0.000228	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—NOD2—psoriatic arthritis	0.00013	0.000221	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CRP—psoriatic arthritis	0.000126	0.000214	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CRP—psoriatic arthritis	0.000122	0.000208	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—HLA-DRB1—psoriatic arthritis	0.000121	0.000205	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CRP—psoriatic arthritis	0.000119	0.000201	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—HLA-DRB1—psoriatic arthritis	0.000117	0.000199	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—HLA-DRB1—psoriatic arthritis	0.000114	0.000193	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—TNF—psoriatic arthritis	0.000108	0.000183	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HLA-B—psoriatic arthritis	0.000105	0.000178	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—NOS2—psoriatic arthritis	0.000103	0.000175	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CRP—psoriatic arthritis	9.27e-05	0.000157	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HLA-DRB1—psoriatic arthritis	8.88e-05	0.000151	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—TNF—psoriatic arthritis	8.16e-05	0.000138	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—NOS2—psoriatic arthritis	7.8e-05	0.000132	CbGpPWpGaD
